<DOC>
	<DOC>NCT02441972</DOC>
	<brief_summary>The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.</brief_summary>
	<brief_title>Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics</brief_title>
	<detailed_description>Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma, Bronchogenic</mesh_term>
	<mesh_term>Soft Tissue Neoplasms</mesh_term>
	<criteria>1. Volunteers or patients with age more than 18 yeas; 2. The patients have been diagnosed with cancer or suspected with cancer; 3. It must fulfill the ethical requirements and subjects have signed an informed consent. 1. Pregnancy or nursing mothers; 2. Having drugs or alcohol dependence; 3. Hypersensitive to the active or inactive ingredients of the study drug; 4. Having attended other drug clinical trials within three months; 5. Cardiac functional insufficiency; 6. Hepatic and renal function insufficiency; 7. Hypertensive patients with serious complications; 8. Endangering the safety of life.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>